New Phase 3 data demonstrate superiority of TREMFYA® (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 48

Read also

Three scientists win Nobel Prize

Three scientists win Nobel Prize in chemistry for creating new molecular structure

Boehringer

Boehringer bags FDA okay for new pulmonary fibrosis drug

Editas Medicine reports 90% LDL-C reduction in preclinical studies

CAMBRIDGE, Mass. - Editas Medicine, Inc., whose stock has surged over 260% in the past six months according to InvestingPro data

China accounts for one-fifth of global drugs in development

China-based companies are responsible for 20% of drugs in development globally, reflecting the powerhouse role the country has embraced in the pharmaceutical industry.